Part III - BEBAC • Consultancy Services for Bioequivalence

Taking a Biostatistical Approach to Designing a BioequivalenceB
Study: Ensuring Success through Effective Planning (3/3)
Statistical Assumptions
20 mg XYZ s.d. (405 subjects)
min 2.73, Q 1 3.49, median 3.71, Q 3 4.01, max 4.90
2.32 2.86 3.39 3.93 4.46 5.00
ln (AUC ∞ ) [ng×h/mL]
Bioequivalence & Bioavailability Studies | Munich, 252
October 2010
114 • 162